CLEE011A2301 Study of a new drug for hormone receptor positive breast

• Research type

  Research Study

• Full title

  A randomized double-blind, placebo-controlled study of LEE011 in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease

• IRAS ID

  146264

• Contact name

  David Cameron

• Contact email

  d.cameron@ed.ac.uk

• Sponsor organisation

  Novartis Pharmaceuticals UK Limited

• Eudract number

  2013-003084-61

• Clinicaltrials.gov Identifier

  NCT01958021

• Research summary

  Summary of Results
  A lay summary will not be published. Per Novartis SOPs, we commit to providing a plain language summary for studies with approved final protocol synopsis from 01 Sep 2018.

• REC name

  West of Scotland REC 1

• REC reference

  14/WS/0109

• Date of REC Opinion

  21 May 2014

• REC opinion

  Further Information Favourable Opinion